Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295981 · ClinicalTrials.gov registry record · Phase 3
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
A Phase 3 study of Giant Cell Tumor of Bone, sponsored by St. Louis University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 16
- Study locations
NCT03295981 is a Phase 3 study of Giant Cell Tumor of Bone that is actively recruiting participants, run by St. Louis University. The registered enrollment target is 120 participants, below the 305-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 14 states.
The verdict
NCT03295981, a Phase 3 study of Giant Cell Tumor of Bone, is actively recruiting participants, sponsored by St. Louis University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (16)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California - Los Angeles - Los Angeles
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas - Overland Park
Maryland
- Johns Hopkins University Hospital - Baltimore
Missouri
- Saint Louis University - St Louis
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03295981
The ClinicalTrials.gov registry entry for NCT03295981 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 305-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (61% lower). The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Giant Cell Tumor of Bone appearing as the primary indexed condition, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT03295981 reports 16 study locations spanning 14 distinct geographic areas - top geographies include Massachusetts, California, Indiana.
Frequently Asked Questions
What is clinical trial NCT03295981 about?
NCT03295981 is a clinical study titled "Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone". The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of ...
What is the current status of trial NCT03295981?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-05-03. Estimated completion is 2028-01.
What conditions does trial NCT03295981 study?
This clinical trial studies the following conditions: Giant Cell Tumor of Bone.
What interventions are being tested in trial NCT03295981?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT03295981?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03295981 being conducted?
This trial has 16 study locations across California, Indiana, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Tumor of Bone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROMIS and Mobility Evaluation in Sarcoma Patients
RECRUITING
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.